| 1 |
33805415 | UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. | 2021 Mar 29 |
3 |
| 2 |
31640912 | Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. | 2020 Feb |
4 |
| 3 |
30810774 | Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38. | 2019 May |
5 |
| 4 |
31445021 | Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. | 2019 Nov |
1 |
| 5 |
24107802 | Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. | 2013 Nov |
1 |
| 6 |
20389299 | Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. | 2010 Apr 27 |
4 |